Get the Stockscreener App
26.15
4.33%
-1.2298
Arrivent Biopharma Inc stock is traded at $26.15, with a volume of 163.50K.
It is down -4.33% in the last 24 hours and down -2.40% over the past month.
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$27.38
Open:
$26.98
24h Volume:
163.50K
Relative Volume:
1.09
Market Cap:
$922.63M
Revenue:
-
Net Income/Loss:
$-81.05M
P/E Ratio:
-9.9688
EPS:
-2.6232
Net Cash Flow:
$-68.97M
1W Performance:
-8.22%
1M Performance:
-2.40%
6M Performance:
+20.44%
1Y Performance:
+18.21%
1-Day Range:
$25.80
$27.39
1-Week Range:
$25.80
$29.57
52-Week Range:
$14.35
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
26.16 | 922.63M | 0 | -81.05M | -68.97M | -2.6232 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.10 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.98 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.32 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.92 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
Arrivent Biopharma Inc Stock (AVBP) Latest News
Short Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Expands By 13.1% - MarketBeat
Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - News & Insights
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Bought by JPMorgan Chase & Co. - Defense World
(AVBP) Trading Signals - Stock Traders Daily
ArriVent in Newtown Square Sees Big Potential in New Cancer Drug - DELCO.Today
Abbvie seeks molecular glue degraders from Neomorph - BioCentury
ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma - MSN
Equities Analysts Set Expectations for AVBP Q1 Earnings - Defense World
HC Wainwright Issues Positive Estimate for AVBP Earnings - MarketBeat
More China ADCs: Arrivent gets GI cancer drug in $1.2B Lepu deal - BioWorld Online
ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright - Yahoo Finance
ArriVent Biopharma enters license agreement with Lepu Biopharma - MSN
Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim - MedCity News
Intellia makes progress on HAE study; 2 more China drug deals - BioPharma Dive
ArriVent inks ADC licensing deal with Lepu Biopharma - The Pharma Letter
ArriVent bets big on experimental cancer drug with potential $1B licensing deal - The Business Journals
Arrivent Biopharma licenses ex-China rights to Lepu’s ADC for gastrointestinal cancers - BioWorld Online
ArriVent Joins Chinese Licensing Trend With Potential $1.2B+ ADC Deal with Lepu - BioSpace
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers - The Manila Times
Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the - Digital More
Lepu Biopharma Co., Ltd. Enters into an Exclusive Licensing Agreement with Arrivent Biopharma, Inc - Marketscreener.com
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma - WICZ
Lepu Biopharma Grants Exclusive License for Novel ADC MRG007 to ArriVent - TipRanks
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers - The Manila Times
ArriVent BioPharma Secures Global Rights to Promising Cancer Drug MRG007 in $1.2B Deal - StockTitan
(AVBP) Investment Analysis - Stock Traders Daily
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 13.1% in December - MarketBeat
Windtree Therapeutics Secures Patent in Japan for Cancer Treatment Platform - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap DownWhat's Next? - MarketBeat
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Barclays PLC Has $976,000 Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Jane Street Group LLC Has $250,000 Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate - Simply Wall St
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 5%Should You Sell? - MarketBeat
Geode Capital Management LLC Increases Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Barclays PLC Increases Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Stock Position Increased by Geode Capital Management LLC - MarketBeat
Barclays PLC Buys 38,132 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
(AVBP) Proactive Strategies - Stock Traders Daily
State Street Corp Acquires 323,186 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Stake Lifted by State Street Corp - Defense World
(AVBP) Pivots Trading Plans and Risk Controls - Stock Traders Daily
The Manufacturers Life Insurance Company Purchases Shares of 10,234 ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 6.1% in November - MarketBeat
Charles Schwab Investment Management Inc. Buys 122,641 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
BNP Paribas Financial Markets Raises Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Fmr LLC Purchases 169,514 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):